Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 1
1987 1
1988 7
1989 3
1990 19
1991 7
1992 2
1993 13
1994 10
1995 9
1996 17
1997 13
1998 9
1999 17
2000 17
2001 12
2002 11
2003 13
2004 16
2005 7
2006 5
2007 8
2008 17
2009 11
2010 7
2011 11
2012 5
2013 5
2014 8
2015 9
2016 6
2017 5
2018 4
2019 2
2020 1
2021 2
2022 5
2023 6
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Madan RA, et al. Oncologist. 2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. Oncologist. 2023. PMID: 37134294 Free PMC article. Clinical Trial.
RESULTS: Thirty-three patients randomized to flutamide and 31 to flutamide+vaccine. The median age was 71.8 and 69.8 years, respectively. ...CONCLUSION: The combination of flutamide+PROSTVAC did not improve outcomes in men with nmCRPC compared with flutami …
RESULTS: Thirty-three patients randomized to flutamide and 31 to flutamide+vaccine. The median age was 71.8 and 69.8 years, re …
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Flutamide in treatment of benign prostatic hypertrophy.
Stone NN. Stone NN. Urology. 1989 Oct;34(4 Suppl):64-8; discussion 87-96. doi: 10.1016/0090-4295(89)90236-7. Urology. 1989. PMID: 2477936 Clinical Trial.
Only 4 patients (11%) had significant adverse reactions to flutamide; these reactions included breast pain and diarrhea. No cases of impotence occurred. It was concluded that flutamide may be a safe and effective drug for the treatment of symptomatic BPH....
Only 4 patients (11%) had significant adverse reactions to flutamide; these reactions included breast pain and diarrhea. No cases of …
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Iguchi T, Tamada S, Kato M, Yasuda S, Machida Y, Ohmachi T, Ishii K, Iwata H, Yamamoto S, Kanamaru T, Morimoto K, Hase T, Tashiro K, Harimoto K, Deguchi T, Adachi T, Iwamoto K, Takegaki Y, Nakatani T. Iguchi T, et al. Int J Clin Oncol. 2020 Mar;25(3):486-494. doi: 10.1007/s10147-019-01554-3. Epub 2019 Sep 28. Int J Clin Oncol. 2020. PMID: 31564004 Clinical Trial.
BACKGROUND: Before the androgen target therapy era, flutamide was widely used for castration-resistant prostate cancer in Japan. Enzalutamide is currently the recommended treatment; however, the efficacy and safety of enzalutamide and flutamide after combined androg …
BACKGROUND: Before the androgen target therapy era, flutamide was widely used for castration-resistant prostate cancer in Japan. Enza …
Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
Faghihi G, Iraji F, Siadat AH, Saber M, Jelvan M, Hoseyni MS. Faghihi G, et al. J Cosmet Dermatol. 2022 Oct;21(10):4447-4453. doi: 10.1111/jocd.14788. Epub 2022 Feb 18. J Cosmet Dermatol. 2022. PMID: 35152531 Clinical Trial.
Minoxidil and finasteride are regarded as the first-line treatments with antiandrogens and flutamide are considered as the alternative choices. In the current study, we evaluated the efficacy of combination therapy with topical 2%flutamide plus 5% minoxidil vs. %5 m …
Minoxidil and finasteride are regarded as the first-line treatments with antiandrogens and flutamide are considered as the alternativ …
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Dumesic DA, Winnett C, Lu G, Grogan TR, Abbott DH, Naik R, Chazenbalk GD. Dumesic DA, et al. Fertil Steril. 2023 Jan;119(1):116-126. doi: 10.1016/j.fertnstert.2022.09.324. Epub 2022 Nov 15. Fertil Steril. 2023. PMID: 36400597 Free PMC article. Clinical Trial.
Interventions were repeated in women with PCOS after 6-month administration of flutamide (125 mg orally daily) vs. placebo. MAIN OUTCOME MEASURE(S): Clinical parameters and lipid accumulation in newly formed adipocytes derived from SC abdominal ASCs in vitro were compared …
Interventions were repeated in women with PCOS after 6-month administration of flutamide (125 mg orally daily) vs. placebo. MAIN OUTC …
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M 3rd, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Jones CU, et al. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):294-303. doi: 10.1016/j.ijrobp.2021.08.031. Epub 2021 Sep 1. Int J Radiat Oncol Biol Phys. 2022. PMID: 34481017 Free PMC article. Clinical Trial.
Patients were stratified by PSA, tumor grade, and surgical versus clinical nodal staging. ADT was flutamide with either goserelin or leuprolide for 4 months. Prostate RT (66.6 Gy) was started after 2 months. ...
Patients were stratified by PSA, tumor grade, and surgical versus clinical nodal staging. ADT was flutamide with either goserelin or …
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Boccon-Gibod L, et al. Eur Urol. 1997;32(4):391-5; discussion 395-6. Eur Urol. 1997. PMID: 9412794 Clinical Trial.
Side effects were dominated by gynecomastia, hot flushes in both groups, breast tenderness and diarrhea in the flutamide group. Overall, 4 (10%) of the patients in the flutamide group withdrew from therapy because of side effects. The impact of flutamide on s …
Side effects were dominated by gynecomastia, hot flushes in both groups, breast tenderness and diarrhea in the flutamide group. Overa …
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T, Tamada S, Kato M, Yasuda S, Yamasaki T, Nakatani T. Iguchi T, et al. BMC Cancer. 2019 Apr 11;19(1):339. doi: 10.1186/s12885-019-5526-3. BMC Cancer. 2019. PMID: 30971225 Free PMC article. Clinical Trial.
The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to disease progression with enzalutamide over flutamide may translate to better overall survival. However, flutamide may be more acce …
The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to dise …
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
Fosså SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L. Fosså SD, et al. J Clin Oncol. 2001 Jan 1;19(1):62-71. doi: 10.1200/JCO.2001.19.1.62. J Clin Oncol. 2001. PMID: 11134196 Clinical Trial.
RESULTS: There was no difference between the groups in median TTP (prednisone, 3.4 months; flutamide, 2.3 months) or overall survival (prednisone, 10.6 months; flutamide, 11.2 months). In the prednisone group, 56% of the patients experienced a subjective response, c …
RESULTS: There was no difference between the groups in median TTP (prednisone, 3.4 months; flutamide, 2.3 months) or overall survival …
303 results

Searches related to "flutamide"